Progress of targeted therapy for chronic myeloid leukemia
10.3760/cma.j.cn115356-20201211-00299
- VernacularTitle:慢性粒细胞白血病靶向治疗研究进展
- Author:
Jiaqi CHEN
1
;
Fang WANG
;
Wenjun TIAN
;
Hongxing LIU
Author Information
1. 河北燕达陆道培医院检验医学科，河北 廊坊 065201
- Keywords:
Leukemia, myelogenous, chronic;
Molecular targeted therapy;
Tyrosine kinase inhibitor
- From:
Journal of Leukemia & Lymphoma
2021;30(6):325-328
- CountryChina
- Language:Chinese
-
Abstract:
The application of tyrosine kinase inhibitors (TKI) has revolutionarily improved the treatment outcome and survival of patients with chronic myeloid leukemia (CML). The new purpose of the current CML treatment is to achieve a sustained deep molecular biological response to reduce the relapse because of drug resistance and even to achieve treatment-free remission maintenance and cure of the disease. Four kinds of TKI have been approved internationally for the first-line treatment of newly diagnosed chronic-phase CML, and there are constantly new drugs and treatment regimens in development and clinical research. This article introduces the research progress of targeted therapy for CML in combination with the related reports at the 62nd American Society of Hematology Annual Meeting.
